---
title: "An oligodendrocyte silencer element underlies the pathogenic impact of lamin B1 structural variants"
date: 2025-11-05
tags: ["silencer", "oligodendrocyte", "LMNB1", "PRC2", "CTCF", "3D chromatin", "ADLD", "leukodystrophy"]
journal: "Nature Communications"
doi: "10.1038/s41467-025-56378-9"
pmid: "39910058"
pmcid: "PMC11799162"
pubdate_issue: "2025-02-05"
pubdate_epub: "2025-02-05"
license: "CC BY 4.0"
links:
  - name: "Full text (Nature)"
    url: "https://www.nature.com/articles/s41467-025-56378-9"
  - name: "PDF (Nature)"
    url: "https://www.nature.com/articles/s41467-025-56378-9.pdf"
  - name: "PubMed"
    url: "https://pubmed.ncbi.nlm.nih.gov/39910058/"
  - name: "Free full text (PMC)"
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC11799162/"
---

A non-coding **silencer** near **LMNB1** constrains lamin B1 expression specifically in **oligodendrocytes** via **CTCF‑mediated looping** and **PRC2** recruitment. Loss of this element—through upstream deletions or tandem duplications—drives overexpression and explains the tissue‑specific pathology of **autosomal dominant leukodystrophy (ADLD)**.

<!--more-->

## Abstract (concise summary)

Investigating families with **LMNB1** tandem duplications that surprisingly **do not** show demyelination, alongside ADLD tissues, CRISPR‑edited cell lines, and mouse models,
the authors identify an **oligodendrocyte‑specific silencer**. This element contains **CTCF** sites that form **3D chromatin loops** and recruit **PRC2**, reducing LMNB1 transcription
in oligodendrocytes. **Loss of the silencer** (by upstream deletion) or **functional uncoupling** (with certain duplications) elevates LMNB1 expression and underpins ADLD’s
**cell‑type specificity** and pathogenesis.

## Key takeaways

- **Mechanism**: CTCF‑anchored looping plus **PRC2‑mediated repression** keeps LMNB1 low in oligodendrocytes; removing the element lifts repression.
- **Evidence**: Multi‑family human genetics, ATAC/ChIP, CRISPR editing, reporter assays, RNA/protein readouts, and **mouse models** converge on the same mechanism.
- **Clinical lens**: Explains why LMNB1 dosage changes cause **CNS‑restricted demyelination**, despite broad LMNB1 expression.
- **Therapeutic angle**: Restoring the silencer’s function (synthetic silencers/insulators, epigenetic targeting) could normalize LMNB1 in ADLD.

## Suggested citation

Nmezi B, Rodriguez Bey G, DeFrancesco Oranburg T, *et al.* **An oligodendrocyte silencer element underlies the pathogenic impact of lamin B1 structural variants.**
*Nat Commun.* 2025;16(1):1373. doi:10.1038/s41467-025-56378-9.
